– Kidney Disease Treatment into a New Era of Precision Management At the 62nd Congress of the European Renal Association…
Browsing: BioTech
At the 62nd European Renal Association Congress (ERA 2025), Everest Medicines unveiled new clinical data on EVER001 (previously known as…
Key Highlights Clinical trial to evaluate the safety and efficacy of YK012 in primary membranous nephropathy Globally, this is the…
– Over 1,000 investment and business matching meetings lined up underscoring Hong Kong’s role as a healthcare investment hub -…
– Asia Summit on Global Health and Medical and Healthcare Fair open concurrently – Global healthcare leaders gather in Hong…
– Offer price of S$0.25 per share is at an attractive premium of 61.3% over the last traded price being…
Everest Medicines (HKG: 1952) today announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from…
With six newly established, identical BSL-2 laboratories now operational, biologics CDMO Northway Biotech can conduct VCS programs for up to…
– Results from the first patient cohort (N=5) of an open-label proof of concept academic study with low-dose IL-2 and…
HighTide Therapeutics, Inc. (HKG: 2511), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic…
Everest Medicines (HKG: 1952, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization…
– Continuoued to consolidate The leading position of nuclear medicine and facilitated the development of nuclear medical equipment as a…
HighTide Therapeutics Announces HTD1801 Meets the Primary Endpoints in Two Phase 3 Clinical Trials in Patients with Type 2 Diabetes…
– 6,657 total visitors, including 5,908 unique attendees – a 23% increase from the previous edition in 2023 – 300+…
April 9, Hebe Biotechnology Pte Ltd (Hebe Bio), a Singapore-based innovator in metabolic health therapeutics, today announced the appointment of Hannes Hentze, PhD,…
– Potentially a First-and Best-in-Class Product – Combining Deep Pruritus Relief, Effective Skin Clearance, and a Well-tolerated Safety Profile SinoMab…
– HuaTangNing completed its first full year for reimbursement under the National Reimbursement Drug List (NRDL), with continued expansion in…
Awards highlight Avantor’s commitment to the Biopharma industry Avantor Inc., a leading global provider of mission-critical products and services to…
– Dual Success of Innovative Drugs and Generic Drugs – Revenue Recorded RMB28.87 Billion – Adjusted non-HKFRS Profit Attributable to…
On March 17th, the highly anticipated 7th Commendation and Exchange Conference for the Leading Figures in Shanghai’s Industry and Commerce…